2010
Recombinant HCV antigen and HIV antigen were developed.
2011
Recombinant TP antigen and enzyme markers were developed.
2012
A specific blocker was developed to eliminate the interfering substances in immune detection and significantly improve the specificity of immune detection reagents.
2013
Successfully completed the labeling of small molecule hapten: enzyme markers and BSA conjugates of T3, T4, progesterone, testosterone, estradiol, estriol, aldosterone and cortisol; Several project antibodies for immunoturbidimetry have been newly developed; A double antigen sandwich method was established to detect HCV total antibody, and HCV antigen was directly labeled to realize the real two-step detection of HCV total antibody.
2014
The specific monoclonal antibody of HCV core region has been developed, and continuous efforts have been made to realize the joint detection of HCV antigen and antibody.
2015
The raw materials of alkaline phosphatase (ALP) marker and acridine ester (AE) marker were introduced.
2016
Develop highly sensitive troponin monoclonal antibody and HbA1c monoclonal antibody for immunoturbidimetry, and successfully launch the detection antibody of cardiovascular disease markers; Many products are exported to the international market.
2017
Establish immunofluorescence chromatography platform and develop antigen antibody raw materials supporting immunofluorescence chromatography platform.
2018
Dengue NS1 paired monoclonal antibody was developed; And further optimize the raw materials for the joint detection of HCV antigen and antibody.
2019
A series of paired monoclonal antibodies against inflammatory factors and new raw materials for renal function markers were developed.
